Juno Announces Data Presentations At The AACR Annual Meeting

SEATTLE--(BUSINESS WIRE)--Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer, today announced the Company, in partnership with its collaborators, will present clinical and pre-clinical data from multiple product candidates at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2016 in New Orleans, Louisiana from April 16-20.